Madrid – we’re here in Spain for the 2014 Congress of the European Society for Medical Oncology (ESMO). It’s proven to be a challenging and frustrating meeting on multiple levels so far, but hopefully it will redeem itself over the weekend as new data that changes the standard of care for cancer patients is presented.
At the end of the day it’s all about the data and making a difference to the lives of cancer patients.
The highlight of the meeting so far was yesterday’s Roche media briefing and the presentation by Dan Chen MD PhD on how the company is making advances in immunotherapy. We’ll be writing up the data he mentioned as it’s presented at the Congress. The quote he showed from Ira Mellman, PhD about the promise of Immunotherapy is one that resonates with us:
At prior ECCO/ESMO’s we’ve written about the industry satellite symposia that take place, many of which feature world-class experts talking about new drugs in development or the treatment landscape. It’s a big disappointment to be excluded from these events for the first time at #ESMO14, especially as many are educational in content or even organized by Continuing Medical Education (CME) companies.
That said, by dint of the fact ESMO can accept data several months after the ASCO abstracts have closed there is new data to talk about at this meeting and we have a very full schedule of sessions to attend today at the Congress.
If you would like to read more about which sessions we’ll be in and our initial impressions of data during the day, do sign-in if you’re a subscriber or sign up to keep abreast as the data rolls out.
The 2014 European Society for Medical Oncology (ESMO) Congress starts this weekend in Madrid, and it finally feels like it is starting to take off with the release today at lunch-time in Europe of the oral abstracts (with the exception of late breakers) to be presented at the meeting.
This blog post is a preview of some of the oral abstracts that caught my attention in a quick preview this afternoon while in Paris en-route to Madrid.
Following its success at ASCO (one subscriber told us it helped him schedule which sessions to attend, another that it enabled him to question his team on what was really hot at the meeting), we’ll be writing a daily blog on Saturday, Sunday and Monday from ESMO.
It’s going to be a live blog in the sense that we plan to regularly update it during the day, and it will include details of which sessions we are in and our initial impressions of data that catches our interest.
More in-depth posts will follow later.
Back to the oral abstracts, subscribers can login below to read about some of the abstracts that have caught my attention. If you are not yet a subscriber, we do hope you will consider joining what is an exclusive club.
If you can only afford to sign up for a quarter you’re in for a treat as in addition to ESMO we will be covering in person two other major medical meetings this fall, including ASH in San Francisco, and (for now) you still get to read all our previous coverage!!
PS: we’ve not mentioned the companies and products covered in this introduction, as that would make it too easy for non-subscribers, or those in the media who constantly ask us at conferences for story ideas… we all need an edge 🙂